Personalized Medicine for Metastatic Non-Small Cell Lung Cancer:
Leveraging Immune Competence
Podcast 2: Safety And Quality-Of-Life Considerations For Patients Receiving An Immune Checkpoint Inhibitor
Post-Test/Evaluation

Questions marked with a * are required

15%

Contact Information

First Name

Last Name

Email Address

Credentials/Degree (MD, DO, RN, etc.)

Date of Participation

An 82-year-old woman with a significant smoking history was diagnosed with metastatic squamous NSCLC. Molecular testing of tissue biopsy shows a PD-L1 expression of 90%, with no other actionable alterations. Her performance status is 3. She would like to try systemic therapy. According to the NCCN and American Society of Clinical Oncology NSCLC guidelines, all of the following are preferred regimens for this patient EXCEPT:

Single-agent atezolizumab

Single-agent cemiplimab

Single-agent durvalumab

Single-agent pembrolizumab